With the increasing availability and acceptance of real-world evidence outside of academic and institutional settings, community oncology practices are becoming significant and important consumers of this information. According to a recent presentation delivered by Sarah Alwardt, PhD, Vice President of Data, Evidence & Insights for McKesson Life Sciences, and Nicholas Robert, MD, Medical Director of Data, Evidence & Insights for McKesson Life Sciences and The US Oncology Network, real-world evidence is changing the way regulatory and clinical decisions are evaluated and made, including:

• Demonstration of a therapy's effectiveness
• Label expansions
• Patient outcomes
• Support for clinical trial results
• Changes to product administration protocols